Davutamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, davutamig targets and binds to two different, non-overlapping epitopes on MET expressed on thd tumor cell surface, thereby forming unique davutamig-MET complexes. The binding of davutamig to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.

**Synonyms:** - Anti-c-Met Bispecific Antibody REGN5093 - DAVUTAMIG - MET x MET Bispecific Antibody REGN5093 - METxMET Antibody REGN5093 - METxMET Bispecific Antibody REGN5093 - REGN 5093 - REGN-5093 - REGN5093